To invite:
Constanz Blume, Global Regulatory Affairs, BionTech
Kent Rogers, CEO, Everyone Medicines
Senior EMA Representative
This panel will explore the practical implications that industry and patient organizations need to consider when engaging given the evolving landscape of HTA in Europe